Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.
4 affiliations
- 1Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China.
- 2State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Institute for Immunology, China Ministry of Education Key Laboratory of Protein Sciences, Beijing Key Laboratory for Sleep Breathing Disorder, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China.
- 3Institute of Immunology, PLA, Third Military Medical University (Army Medical University), Chongqing International Institute for Immunology, Chongqing, China. [email protected].
- 4State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua-Peking Center for Life Sciences, Institute for Immunology, China Ministry of Education Key Laboratory of Protein Sciences, Beijing Key Laboratory for Sleep Breathing Disorder, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China. [email protected].
Abstract
Humoral immunity, a fundamental branch of adaptive immunity, relies on B lymphocytes and the antibodies they produce to eliminate extracellular pathogens and neutralize toxins. The development, activation, and differentiation of B cells are tightly regulated by epigenetic mechanisms-including DNA methylation, histone modifications, chromatin dynamics, RNA modifications, and noncoding RNAs-that modulate gene expression without altering the DNA sequence, orchestrating key events such as V(D)J recombination, class switch recombination, somatic hypermutation, germinal center reactions, and the generation of memory B cells and plasma cells. In this review, we summarize how these five categories of epigenetic regulators-together with their respective writers, erasers, readers, and effectors-including DNMT3A/3B and TET enzymes, histone-modifying enzymes, SWI/SNF and INO80 remodeling complexes, N6-methyladenosine and 5-methylcytosine machineries, and microRNAs and long noncoding RNAs-collectively govern B-cell fate decisions, from early lineage commitment in the bone marrow, through germinal center dynamics, to terminal differentiation into plasma cells or memory B cells. We further examine how aberrant epigenetic programs in B cells contribute to pathogenesis across four major disease categories: B-cell malignancies, metabolic and cardiovascular diseases, autoimmune disorders, and infectious diseases. We also discuss sex-biased epigenetic mechanisms, particularly escape from X-chromosome inactivation, that may underlie the female predominance of autoimmune diseases. Finally, we discuss the therapeutic implications of targeting epigenetic regulators and assess the potential of epigenetic signatures as biomarkers.
Related
- Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities
- Epigenetic Mechanisms in Neurodegenerative Diseases: From Genetic Regulation to Therapeutic Potential
- Epigenetic regulation of immune checkpoint signaling by microbial metabolites: mechanisms, therapeutic potential, and future perspectives
- Chromatin remodeling in bone organoids: from epigenetic regulation to disease modeling and therapeutic translation.
- Epigenetic Rewiring of Enhancer–Promoter Interactions in Cancer: Mechanisms and Therapeutic Implications
BibTeX
@article{zhang2026epigenetic,
title = {{Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.}},
author = {Shaocun Zhang and Yu Wang and Xin Min and Yuzhang Wu and Wanli Liu},
journal = {Signal transduction and targeted therapy},
year = {2026},
month = oct,
doi = {10.1038/s41392-026-02955-3},
url = {https://europepmc.org/article/MED/42875430},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.
AU - Shaocun Zhang
AU - Yu Wang
AU - Xin Min
AU - Yuzhang Wu
AU - Wanli Liu
PY - 2026
DA - 2026/10/15
JO - Signal transduction and targeted therapy
DO - 10.1038/s41392-026-02955-3
UR - https://europepmc.org/article/MED/42875430
AB - Humoral immunity, a fundamental branch of adaptive immunity, relies on B lymphocytes and the antibodies they produce to eliminate extracellular pathogens and neutralize toxins. The development, activation, and differentiation of B cells are tightly regulated by epigenetic mechanisms-including DNA methylation, histone modifications, chromatin dynamics, RNA modifications, and noncoding RNAs-that modulate gene expression without altering the DNA sequence, orchestrating key events such as V(D)J recombination, class switch recombination, somatic hypermutation, germinal center reactions, and the generation of memory B cells and plasma cells. In this review, we summarize how these five categories of epigenetic regulators-together with their respective writers, erasers, readers, and effectors-including DNMT3A/3B and TET enzymes, histone-modifying enzymes, SWI/SNF and INO80 remodeling complexes, N6-methyladenosine and 5-methylcytosine machineries, and microRNAs and long noncoding RNAs-collectively govern B-cell fate decisions, from early lineage commitment in the bone marrow, through germinal center dynamics, to terminal differentiation into plasma cells or memory B cells. We further examine how aberrant epigenetic programs in B cells contribute to pathogenesis across four major disease categories: B-cell malignancies, metabolic and cardiovascular diseases, autoimmune disorders, and infectious diseases. We also discuss sex-biased epigenetic mechanisms, particularly escape from X-chromosome inactivation, that may underlie the female predominance of autoimmune diseases. Finally, we discuss the therapeutic implications of targeting epigenetic regulators and assess the potential of epigenetic signatures as biomarkers.
SN - 2095-9907
SN - 2059-3635
ER -